157 related articles for article (PubMed ID: 33314236)
1. Determination of selpercatinib, a RET kinase inhibitor, in rat plasma and its application to a pharmacokinetic study.
Wang W; Shi L; Jin L; Wang K
Biomed Chromatogr; 2021 May; 35(5):e5052. PubMed ID: 33314236
[TBL] [Abstract][Full Text] [Related]
2. Quantitative bioanalytical assay for the selective RET inhibitors selpercatinib and pralsetinib in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry.
Şentürk R; Wang Y; Schinkel AH; Beijnen JH; Sparidans RW
J Chromatogr B Analyt Technol Biomed Life Sci; 2020 Jun; 1147():122131. PubMed ID: 32416592
[TBL] [Abstract][Full Text] [Related]
3. Development and Validation of a LC-MS/MS Method for Quantification of Mobocertinib (TAK-788) in Plasma and its Application to Pharmacokinetic Study in Rats.
Li B; Wang J; Dou X; Zhang X; Xue X; Xu Q; Ran W; Xiong S
Comb Chem High Throughput Screen; 2021; 24(9):1410-1416. PubMed ID: 33155888
[TBL] [Abstract][Full Text] [Related]
4. Assessment of In Silico and In Vitro Selpercatinib Metabolic Stability in Human Liver Microsomes Using a Validated LC-MS/MS Method.
Attwa MW; AlRabiah H; Mostafa GAE; Bakheit AH; Kadi AA
Molecules; 2023 Mar; 28(6):. PubMed ID: 36985590
[TBL] [Abstract][Full Text] [Related]
5. Development and validation of a UPLC-MS/MS method for determination of motesanib in plasma: Application to metabolic stability and pharmacokinetic studies in rats.
Ezzeldin E; Iqbal M; Al-Salahi R; El-Nahhas T
J Pharm Biomed Anal; 2019 Mar; 166():244-251. PubMed ID: 30665192
[TBL] [Abstract][Full Text] [Related]
6. ABCB1 and ABCG2, but not CYP3A4 limit oral availability and brain accumulation of the RET inhibitor pralsetinib.
Wang Y; Sparidans RW; Potters S; Lebre MC; Beijnen JH; Schinkel AH
Pharmacol Res; 2021 Oct; 172():105850. PubMed ID: 34450308
[TBL] [Abstract][Full Text] [Related]
7. Selpercatinib: First Approval.
Markham A
Drugs; 2020 Jul; 80(11):1119-1124. PubMed ID: 32557397
[TBL] [Abstract][Full Text] [Related]
8. Determination of tyrosine kinase inhibitor afatinib in rat plasma using LC-MS/MS and its application to in vivo pharmacokinetic studies of afatinib liposomes.
Lu X; Liu S; Yang X; Han M; Sun K
J Pharm Biomed Anal; 2019 Feb; 164():181-186. PubMed ID: 30390560
[TBL] [Abstract][Full Text] [Related]
9. Highly sensitive method for the determination of a novel triple kinase inhibitor with anti-cancer activity, JI-101, in rat plasma by liquid chromatography-electrospray ionization tandem mass spectrometry: application to a pharmacokinetic study.
Gurav SD; Gilibili RR; Jeniffer S; Giri S; Srinivas NR; Mullangi R
Biomed Chromatogr; 2011 Jul; 25(7):794-800. PubMed ID: 20872957
[TBL] [Abstract][Full Text] [Related]
10. Liquid chromatography-electrospray ionization-tandem mass spectrometry method for quantitative estimation of new imiqualine leads with potent anticancer activities in rat and mouse plasma. Application to a pharmacokinetic study in mice.
Chouchou A; Marion B; Enjalbal C; Roques C; Cuq P; Bonnet PA; Bressolle-Gomeni FMM; Deleuze-Masquéfa C
J Pharm Biomed Anal; 2018 Jan; 148():369-379. PubMed ID: 29111492
[TBL] [Abstract][Full Text] [Related]
11. Development and validation of an LC-MS/MS method for the determination of SB-505124 in rat plasma: Application to pharmacokinetic study.
Jiang J; Zhang Y; Zhang Q; Li Y; Gong T; Zhang Z; Ding R; Sun X
J Pharm Biomed Anal; 2016 Jan; 117():205-9. PubMed ID: 26363490
[TBL] [Abstract][Full Text] [Related]
12. Simultaneous determination of alflutinib and its active metabolite in human plasma using liquid chromatography-tandem mass spectrometry.
Liu X; Li W; Zhang Y; Jiang Y; Zhao Q; Zhong D
J Pharm Biomed Anal; 2019 Nov; 176():112735. PubMed ID: 31394305
[TBL] [Abstract][Full Text] [Related]
13. Simultaneous and rapid determination of 12 tyrosine kinase inhibitors by LC-MS/MS in human plasma: Application to therapeutic drug monitoring in patients with non-small cell lung cancer.
Zhou L; Wang S; Chen M; Huang S; Zhang M; Bao W; Bao A; Zhang P; Guo H; Liu Z; Xie G; Gao J; Wu Z; Lou Y; Fan G
J Chromatogr B Analyt Technol Biomed Life Sci; 2021 Jun; 1175():122752. PubMed ID: 33991955
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of Selpercatinib in
Drilon A; Oxnard GR; Tan DSW; Loong HHF; Johnson M; Gainor J; McCoach CE; Gautschi O; Besse B; Cho BC; Peled N; Weiss J; Kim YJ; Ohe Y; Nishio M; Park K; Patel J; Seto T; Sakamoto T; Rosen E; Shah MH; Barlesi F; Cassier PA; Bazhenova L; De Braud F; Garralda E; Velcheti V; Satouchi M; Ohashi K; Pennell NA; Reckamp KL; Dy GK; Wolf J; Solomon B; Falchook G; Ebata K; Nguyen M; Nair B; Zhu EY; Yang L; Huang X; Olek E; Rothenberg SM; Goto K; Subbiah V
N Engl J Med; 2020 Aug; 383(9):813-824. PubMed ID: 32846060
[TBL] [Abstract][Full Text] [Related]
15. A selective and robust UPLC-MS/MS method for the simultaneous quantitative determination of anlotinib, ceritinib and ibrutinib in rat plasma and its application to a pharmacokinetic study.
Du P; Guan Y; An Z; Li P; Liu L
Analyst; 2019 Sep; 144(18):5462-5471. PubMed ID: 31380858
[TBL] [Abstract][Full Text] [Related]
16. Determination of Puquitinib in Human Plasma by HPLC-ESI MS/MS: Application to Pharmacokinetic Study.
Zhan J; Ding Y; Zou B; Liao H; Jiang W; Li S
Eur J Drug Metab Pharmacokinet; 2018 Oct; 43(5):555-564. PubMed ID: 29520719
[TBL] [Abstract][Full Text] [Related]
17. Response to the Selective RET Inhibitor Selpercatinib (LOXO-292) in a Patient With RET Fusion-positive Atypical Lung Carcinoid.
Kander EM; Shah MH; Zhou Y; Goyal A; Palmer JD; Owen DH; Shilo K; Patel G; Raval RR; Gonzalez J; Nguyen M; Olek E; Kherani J; Rothenberg SM; Konda B
Clin Lung Cancer; 2021 May; 22(3):e442-e445. PubMed ID: 32660930
[No Abstract] [Full Text] [Related]
18. A sensitive bioanalytical method for quantitative determination of resiniferatoxin in rat plasma using ultra-high performance liquid chromatography coupled to tandem mass spectrometry and its application in pharmacokinetic study.
Sharma PK; Avula B; Panda A; Wang YH; Khan IA; Murthy SN
J Pharm Biomed Anal; 2019 Feb; 165():284-291. PubMed ID: 30576973
[TBL] [Abstract][Full Text] [Related]
19. Development and full validation of an LC-MS/MS methodology to quantify capmatinib (INC280) following intragastric administration to rats.
Fan X; Yang G; Cui W; Liu Q; Zhang Z; Zhang Z
Biomed Chromatogr; 2020 Mar; 34(3):e4768. PubMed ID: 31821576
[TBL] [Abstract][Full Text] [Related]
20. Quantification and pharmacokinetics of crizotinib in rats by liquid chromatography-tandem mass spectrometry.
Qiu F; Gu Y; Wang T; Gao Y; Li X; Gao X; Cheng S
Biomed Chromatogr; 2016 Jun; 30(6):962-8. PubMed ID: 26467669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
